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ABSTRACT
The protein kinase ATR plays pivotal roles in DNA
repair, cell cycle checkpoint engagement and DNA
replication. Consequently, ATR inhibitors (ATRi) are
in clinical development for the treatment of can-
cers, including tumours harbouring mutations in the
related kinase ATM. However, it still remains un-
clear which functions and pathways dominate long-
term ATRi efficacy, and how these vary between
clinically relevant genetic backgrounds. Elucidating
common and genetic-background specific mecha-
nisms of ATRi efficacy could therefore assist in pa-
tient stratification and pre-empting drug resistance.
Here, we use CRISPR–Cas9 genome-wide screen-
ing in ATM-deficient and proficient mouse embryonic
stem cells to interrogate cell fitness following treat-
ment with the ATRi, ceralasertib. We identify factors
that enhance or suppress ATRi efficacy, with a sub-
set of these requiring intact ATM signalling. Strik-
ingly, two of the strongest resistance-gene hits in
both ATM-proficient and ATM-deficient cells encode
Cyclin C and CDK8: members of the CDK8 kinase
module for the RNA polymerase II mediator com-
plex. We show that Cyclin C/CDK8 loss reduces
S-phase DNA:RNA hybrid formation, transcription-
replication stress, and ultimately micronuclei forma-
tion induced by ATRi. Overall, our work identifies
novel biomarkers of ATRi efficacy in ATM-proficient
and ATM-deficient cells, and highlights transcription-
associated replication stress as a predominant driver
of ATRi-induced cell death.
INTRODUCTION
Ataxia telangiectasia and Rad3-related (ATR) is a funda-
mental DNA damage response (DDR) protein kinase in-
volved in DNA double-strand break (DSB) signalling and
cell cycle checkpoint engagement, and is also an apical reg-
ulator of the replication stress response (RSR) (1–3). ATR’s
roles in the stabilisation and restart of stalled DNA replica-
tion forks are important for maintaining genomic integrity
since, in the absence of ATR function, stalled replication
forks are converted into cytotoxic DSBs through replication
fork collapse. ATR also plays pivotal roles in unperturbed
S-phase by regulating dormant replication-origin firing and
controlling the S/G2 cell cycle transition (4). Importantly,
replication stress (5) has been identified as a hallmark of
cancer (6). While this may be in-part due to faster prolifer-
ation rates and nucleotide shortages in S-phase, amplifica-
tion of the oncogenes CCNE1 and MYC specifically induce
replication stress by shortening G1 and promoting firing
of intragenic origins that would otherwise be repressed by
near-completed transcription (7). This also increases con-
flicts between DNA replication and transcription (8), with
such collisions causing genome instability through replica-
tion fork collapse (9,10). Replication stress, particularly in
the absence of replication fork protection, can also lead
to exhaustion of replication protein A (RPA). This results
in insufficient RPA to coat the single-stranded DNA (ss-
DNA) that arises during replication fork stalling or the un-
coupling of the DNA helicase and DNA polymerase, ulti-
mately leading to global replication fork collapse and repli-
cation catastrophe (11). Importantly, ATR’s fundamental
roles in the RSR, including limiting origin firing and pro-
moting nucleotide synthesis, act to prevent RPA exhaustion
and replication catastrophe, and likely present a key survival
mechanism for cancer cells with high endogenous replica-
tion stress.
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Exploiting this concept, ATR inhibitors (ATRi) are in
clinical development for the treatment of cancers (12)
including those with mutations in the related kinase
ataxia telangiectasia mutated (ATM) (13–16), or high en-
dogenous replication stress (17–20). The latter is also
a biomarker for hypersensitivity towards inhibitors of
CHK1 and WEE1 kinases, both of which also play key
roles in the RSR (17). Recent studies using CRISPR–
Cas9 and siRNA screening methodologies identified loss
of POLE3/4, RNASEH2A/B, and ERCC1 as additional
biomarkers of ATRi hypersensitivity (21–23). Similarly,
loss of the cyclin-dependent kinase (CDK)-regulator phos-
phatase CDC25A was found to promote ATRi resistance,
implicating abrogation of the G2/M checkpoint as a major
driver of ATRi efficacy (24). However, these studies have
thus far been performed in wild-type (WT) or TP53 knock-
out cells to facilitate screen performance. This may mean
that identified hits do not fully reflect the drivers of cell
death in tumours harbouring specific genetic defects, such
as mutations in ATM, that are likely to be targeted with
ATR inhibitors in the clinic. In particular, the hypersensi-
tivity of ATM-mutated cancers to ATR inhibition (13–16)
could be driven by over-lapping and redundant functions
of ATM and ATR kinases, given that there are over 700
suggested ATM/ATR substrates harbouring S/T-Q motifs
(25–27). ATM and ATR signalling are already known to
crosstalk to regulate processes including DNA repair, cell
senescence and apoptosis, and cell cycle checkpoint con-
trol (28–31), with roles for ATM in regulating DNA replica-
tion having also been reported (32–35). It is therefore likely
that drivers of ATRi sensitivity and resistance will differ
between ATM-proficient and ATM-deficient cells, mean-
ing that elucidating both common and genetic background-
specific mechanisms of ATRi efficacy will be critical for ac-
curately stratifying patients and pre-empting innate or ac-
quired drug resistance.
To address the above issues, in this study we exam-
ine genetic drivers of ATRi efficacy by performing pooled
CRISPR–Cas9 screens in Atm WT and Atm knockout (KO)
mouse embryonic stem cells (mESCs) using the ATRi, cer-
alasertib (AZD6738) (36). Our ensuing data reveal how
drivers of ATRi efficacy depend on functional ATM ex-
pression, thereby providing further insight into how ATR
and ATM cooperate to maintain genomic integrity. Fur-
thermore, by focusing on the strongest resistance-gene hits
in both ATM-proficient and ATM-deficient cells, we in-
vestigate the mechanism by which loss of Cyclin C or
CDK8, members of the CDK8 kinase module of the RNA
polymerase II (RNAPII) mediator complex, promote resis-
tance to ATR and CHK1 inhibition by limiting DNA:RNA
hybrid formation in S-phase and transcription-associated
replication stress. These findings also suggest new therapeu-
tic opportunities for ATR inhibitors and provide insights
for better stratifying patients and pre-empting innate or ac-
quired drug resistance.
MATERIALS AND METHODS
Cell lines and compounds
Cell line origins and their cell growth media can be found
in Supplementary Methods Table S1. mESC, FaDu and
A549 ATM-knockout cell lines were generated as de-
scribed before (37,38). mESC Cdc25a KO clones #4/5 were
kindly provided by Oscar Fernández-Capetillo (24) and
U2-OS T-Rex GFP-RNase H1(D210N) (RNH1(D210N)-
GFP) or GFP-RNase H1 (RNH1-GFP) cells by Pavel Jan-
scak (39). mESCs were cultured on 0.1% gelatin-coated
tissue culture flasks, and Cas9-expressing cell lines were
maintained in blasticidin (10 g/ml mESC and U2-OS, 5
g/ml HAP-1). AZD6738 and AZD1775 were made by As-
traZeneca. DRB (5,6-dichloro-1-beta-ribo-fuanosyl benz-
imidazole), actinomycin D, aphidicolin, hydroxyurea, car-
boplatin and etoposide were obtained from Sigma-Aldrich.
XL413 (S7547), VE-822 (S27102), LY2603618 (S2626) and
LY2606368 (S7178) were obtained from SelleckChem. CX-
5461 (509265) was obtained from Merck Millipore, and
BRD-6989 (6438) from Tocris. Final assay DMSO concen-
trations were normalised to 1:1000 as required. Recombi-
nant human IFN was obtained from Peprotech (300–02)
and used at a final concentration of 2.5 ng/ml.
In vitro growth and cell viability assays
MTT cell proliferation assays. For each biological repli-
cate (n = 3) cells were seeded as technical replicates at 5000
cells per well of a 96-well plate, 16 h prior to drug treatment.
Following treatment, medium was replaced with 50 l 0.5
mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- diphenylte-
trazolium bromide; thiazolyl blue) in growth media and
cells incubated for a further 4 h. 50 l 10% SDS was then
added to the cells and incubated at 37◦C overnight before
reading absorbance at 595 nm.
Clonogenic survival assays. For each biological replicate
(n = 3), 16 h prior to treatment cells were seeded in trip-
licate in 6-well plates at 500 cells/well (mESC, A549, U2-
OS, HAP-1) or 1500 cells/well (FaDu). ATM KO FaDu
cells were seeded in conditioned media. Cells were incu-
bated with the drug for 6 (mESC, HAP-1) or 9 days (A549,
FaDu, U2-OS) before methanol fixation (mESC) and crys-
tal violet staining. The number of colonies (defined as con-
taining > 30 cells) were counted blind and normalised to
the untreated conditions to account for variations in plating
efficiencies. For short-term treatments, cells were washed
three times with fresh drug-free media following treatment.
Incucyte cell confluency. For each biological replicate, cells
were seeded as technical replicates at 5000 cells per well of
a 96-well plate. Live-cell imaging was acquired at 10× mag-
nification every 2 h, and percentage phase confluency was
quantified using Incucyte ZOOM 2018A software (Essen
Bioscience). Doubling times were calculated in GraphPad
prism V.8 during the exponential growth phase using the
exponential growth equation.
CRISPR–Cas9 screen for resistance and sensitivity to
AZD6738. 1 × 108 Atm WT or KO mESCs were indepen-
dently infected with a pre-packaged lentiviral library at a
MOI (multiplicity of infection) of 0.1, giving a library cover-
age of ∼1000×. The Kosuke Yusa murine v2 sgRNA library
was used (40). After 48 h, 1 × 108 cells/genotype were col-
lected for sequencing and a further 1 × 108 cells treated with
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puromycin (2 g/ml) for 12 days to select for cells with the
stably integrated sgRNA cassette. Following establishment
of puromycin resistance (day 6) cells were partitioned into
three technical replicates and at least 5 × 107 cells (500×)
per sample were maintained in culture for the remainder of
the screen. A total puromycin selection period of 12 days
ensured that even slow-turnover proteins were depleted and
allowed technical replicates to become established as inde-
pendent samples. On day 14, 5 × 107 cells/replicate were
collected for sequencing and 5 × 107 cells/replicate plated
for each genotype and treatment condition. Sixteen hours
later, cells were treated with either DMSO, IC10 AZD6738
(100 nM Atm KO; 350 nM WT) or IC90 AZD6738 (350 nM
Atm KO; 900 nM WT) for 6 days and then replated in drug-
free medium for 48 h recovery. A 6-day treatment period was
chosen to allow the controlled induction of ATRi-driven
cell death through multiple rounds of cell division, using
ATR-selective concentrations of AZD6738, while minimis-
ing the time for genetic drift to occur. IC10 and IC90 are
the inhibitory doses that result in a 10% or 90% reduc-
tion in cell number respectively when assessed in screen-
ing format. On days 2 and 5 of treatment (every 3 days),
cells were passaged and 5 × 107 cells per treatment condi-
tion were re-seeded to ensure that cells were maintained in
optimal conditions and below confluency throughout the
screen. Surviving cells were separately pooled for each con-
dition and replicate and pelleted for DNA extraction and
next-generation sequencing. DNA was extracted at 55◦C
in TAIL buffer (17 mM Tris pH 7.5, 17 mM EDTA, 170
mM NaCl, 0.85% SDS, 1 mg/ml proteinase K), isopropanol
precipitated, purified in 70% ethanol, and dissolved to 200
ng/l in H2O. DNA was amplified by PCR (2 g × 96 reac-
tions, or 960 reactions for 48-hour samples; approximately
319× representation) using Q5 high fidelity polymerase and
extended primers containing Illumina adaptors and bar-
codes for multiplexing. To reduce PCR bias, the number
of cycles was limited to 26, and multiple PCR reactions
were performed in parallel. The product was cleaned us-
ing SPRIselect beads (Beckman Coulter, B23317) and col-
umn purification (Qiagen, 28106), and all samples of the
same genotype multiplexed using q-PCR NEBNext library
quant kit (E7630). The 19 bp sgRNA (along with 1 bp on ei-
ther side) and 8 bp barcode were sequenced on an Illumina
Hiseq1500 system using single-ended reads. An in-house
script was used to count the number of each sgRNA per
pool, and enriched or depleted genes determined by com-
parison of control and treated samples using the software
package MAGeCK (0.5.5). WT IC10 technical replicate 1
was excluded from the analyses due to principal compo-
nent analysis (PCA) indicating that this sample closely re-
sembled the DMSO-treated samples. Given the data repre-
sent technical replicates, data were independently analysed
by both summing the replicates, and by using the MAGeCK
replicate function. Due to noise in low read count essential
genes sometimes confounding drug-treatment results, sgR-
NAs with low read counts in the DMSO control were ex-
cluded prior to analysis (41). No sgRNAs were excluded
for essential gene comparisons between 48 h and day 14
(pre-treatment) samples. For summed analyses, sgRNAs
with DMSO read counts <30 after combining the repli-
cates were excluded (SUM < 30ex). For replicates analy-
ses, sgRNAs with DMSO read counts of 0 in any 2 repli-
cates and <10 in the third were excluded (REP < 10ex).
Drop-out and enrichment hits were determined using each
method at both IC10 and IC90 doses (Supplementary Table
S1), and the analyses which provided the greatest number
of significant hits (false discovery rate (FDR) < 0.1) are vi-
sualised in the main figure panels. The most significant hits
were determined to have a FDR of <0.1, but hits with a
P-value <0.001 were also assessed as potential candidates.
Format of MAGeCK commands used:
Summed analysis: mageck test -k counts.csv -c DMSO -t
ATRi -n results.csv
Replicates analysis: mageck test -k counts.csv -c
‘DMSO1’,‘DMSO2’,‘DMSO3’ -t ‘ATRi1’,‘ATRi2’,‘ATRi3’
-n results.csv
Essential gene analysis: mageck test -k counts.csv -c 48h
-t D14 -n results.csv
Flow cytometry. Cells were seeded at 500 000 cells/well in
6-well plates 18 h prior to treatment. Cells were incubated
with compounds and EdU (5-ethynyl-2′-deoxyuridine; 10
M; Sigma-Aldrich 900584) or EU (5-ethynyl uridine; 1
mM; ab146642) as indicated and fixed in 70% ice-cold
ethanol. Antibody stainings were performed in 1 mg/ml
BSA-PBS as required using the antibodies listed in Sup-
plementary Methods Table S2. The click reactions were
subsequently performed as previously reported (42) before
staining with 1 g/ml DAPI in PBS containing 250 g/ml
RNase A. All samples were acquired using Aurora (Cytek
Biosciences), Fortessa (BD biosciences) or Cytoflex (Beck-
man Coulter) flow cytometers, and analysed in FlowJo
(Tree Star).
Western blot analyses. Cells were lysed in 50 mM Tris pH
7.5, 2% SDS, 10 mM N-ethylmaleimide supplemented with
protease inhibitors (Roche) and phosphatase inhibitors
(Sigma-Aldrich), and heated to 95◦C for 5 min. For chro-
matin fractionations, cells were lysed in CSK buffer (10 mM
PIPES, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 0.7%
Triton X-100, supplemented with protease and phosphatase
inhibitors) for 30 min on ice and centrifuged for 10 min max
speed at 4◦C, with the supernatant removed as the soluble
fraction. The pellet was washed twice in ice-cold PBS, re-
suspended in CSK buffer and syringed to produce the chro-
matin fraction. Equal amounts of lysates were separated on
4–12% Bis-Tris NuPAGE gels and analysed by standard im-
munoblotting using the antibodies listed in Supplementary
Methods Table S2.
Immuno-fluorescence. Cells were plated in 96-well plates
(20 000 cells/well U2-OS, 50 000 cells/well HAP-1) 16 h
prior to treatment. For U2-OS RNH1-GFP cells, 12 000
cells/well were plated and induced 16 h later with 1 ng/ml
doxycycline for 24 h prior to treatment. Cells were incu-
bated with compounds, EdU (10 M) or EU (1 mM) as
indicated, and fixed in 4% PFA for 15 min at room tem-
perature (RT). For H2AX and RPA32 staining, cells were
pre-extracted in ice-cold 0.2% Triton-PBS for 10 min on ice
prior to fixation. Cells were permeabilised in 0.5% Triton-
PBS for 15 min and blocked in 5% BSA in 0.1% PBS–tween
(PBST). As required, the click reactions were performed as
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previously reported (42) before antibody staining. For an-
tibody staining, primary antibodies were incubated at 4◦C
O/N using the antibodies listed in Supplementary Meth-
ods Table S2. Cells were washed 3× in PBST before incuba-
tion with Alexa Fluor secondary antibodies for 1 h at RT in
the dark, followed by DAPI staining (1 g/ml) for 20 min
at RT. Plates were imaged using an Opera Phenix spinning
disc confocal microscope (PerkinElmer) at 40× magnifica-
tion. All data were imported into Harmony image analysis
software (PerkinElmer) for subsequent analyses.
Defining and counting nuclei. Nuclei were defined based on
DAPI intensity. Border objects were removed from analyses.
Defining and counting micronuclei. Micronuclei were ini-
tially defined based upon the DAPI stain using Harmony’s
‘find micronuclei’ function, and further refined based upon
the following parameters: fraction of nucleus area <0.33,
roundness >0.75, area >2 m2, fraction of nucleus inten-
sity >0.25, intensity DAPI CV (%) <36 and distance from
nucleus 0.6–10 m.
Calculating nuclear intensities. Mean intensities were cal-
culated in pre-defined nuclei and used to define EdU posi-
tive nuclei for further analyses as required.
Counting nuclear foci. The ‘find spots’ function was used
to identify foci in pre-defined nuclei, and foci were subse-
quently refined to exclude spots <1 px2.
Proximity ligation assays. The PLA assays were per-
formed as previously described (43), with 20 000 cells/well
plated in 96-well plates 16 h prior to treatment. Plates
were imaged using an Opera Phenix spinning disc confo-
cal microscope (PerkinElmer) at 40× magnification. All
data were imported into Harmony image analysis software
(PerkinElmer) for subsequent analyses.
DsiRNA transfections. DsiRNAs (27-mer Dicer-substrate
short interfering RNAs) were obtained from IDT and
transfected using Lipofectamine RNAiMAX (Invitrogen)
according to manufacturer’s protocol. The non-targeting
siRNA (NTsi) NC was obtained from IDT and used as the
control. Cells were plated for assays 48 h later. DsiRNA se-
quences can be found in Supplementary Methods Table S3.
RNH1(D210N)-GFP reporter assay (39).
RNH1(D210N)-GFP cells were transfected with the
indicated DsiRNAs. Twenty-four hours post transfection,
cells were seeded in 96 well plates in the presence of
doxycycline (1 ng/ml) to induce expression of GFP-RNase
H1(D210N) and treated with inhibitors after 24 h. For
analyses of cell cycle distributions, EdU was added to cell
culture medium at a final concentration of 10 M for 30
min prior to fixation. Cells were pre-extracted (25 mM
HEPES–NaOH pH 7.5, 50 mM NaCl, 1 mM EDTA, 3
mM MgCl2, 0.3 M sucrose and 0.5% Triton X-100) for 4
min on ice before fixation in 4% PFA. EdU click reactions
were performed in buffer containing 100 mM Tris–HCl
(pH 8.5), 2 mM CuSO4, 100 mM sodium ascorbate and 5
M Alexa Fluor 647 azide (Thermo Fisher Scientific) for
20 min, and DNA was counterstained with 1 g/ml DAPI.
Image acquisition was performed on a WiScan Hermes
system (IDEA Bio-Medical) equipped with 40×/0.75 NA
air objective, and nuclear GFP foci counts were analysed
using integrated WiSoft Athena software.
Stable cell line generation. Lentivirus-based CDK8-GFP
and CDK8(D173A)-GFP plasmids were obtained from
VectorBuilder, packaged in HEK293-lentiX cells using sec-
ond generation packaging plasmids, and the lentivirus used
to infect HAP-1 cells. Forty-eight hours later, cells with the
integrated plasmids were selected in puromycin (0.5 g/ml)
for 7 days prior to single-cell plating and clonal expan-
sion. For gene knockouts using CRISPR, synthetic crRNA
(CRISPR RNA) and tracrRNAs (trans-activating RNA)
were obtained from IDT (Supplementary Methods Table
S4), duplexed and transfected into Cas9-expressing cells us-
ing RNAiMAX according to the manufacturer’s instruc-
tions. Pooled editing efficiencies were assessed after 72 h and
cells plated for single-cell expansion. Individual clones were
tested for successful and complete KO via western blotting.
All KO clones used in this study were genotype validated
(Supplementary Table S2) by either TIDe (44) or TOPO-
cloning (Thermofisher, K28002) following genomic DNA
extraction and PCR amplification of the sgRNA-targeted
loci (associated primers can be found in Supplementary
Methods Table S4).
RT-qPCR. RNA was extracted using a RNeasy kit with
on column DNase digestion according to the manufac-
turer’s protocol (Qiagen, 74106). 3 g total RNA (quanti-
fied using a NanoDrop spectrophotometer) was used for re-
verse transcription using SuperScriptIII first-strand synthe-
sis reagents and oligo dT according to the manufacturer’s
protocol (Invitrogen, 18080051). cDNA was diluted in a fi-
nal volume of 200 l nuclease-free water and further di-
luted one in five prior to amplification, resulting in Ct val-
ues in the range of 20–30 cycles. Quantitative PCR was per-
formed using 2× Fast SYBR Green Master mix (Thermo
Fisher Scientific, 4385612) in a final volume of 20 l, using
2 l cDNA (post one in five dilution). For each biological
replicate, individual amplification reactions were performed
in technical triplicates, and primers targeting the house-
keeping gene Gapdh were included in separate wells for each
condition to normalise transcript levels. Primers were de-
signed to span an exon-exon junction using primer-BLAST,
and synthesised by Sigma-Aldrich. Sequences can be found
in Supplementary Methods Table S5. The StepOne Plus
Real Time PCR system (Thermo Fisher Scientific) was used
to obtain raw Ct values, and the comparative Ct method
2–Ct used to quantify transcript levels.
CRISPR-based cell competition assays. Synthetic crRNA
and tracrRNAs were obtained from IDT (Supplementary
Methods Table S4), duplexed and transfected into Cas9-
expressing mESCs using RNAiMAX according to manu-
facturer’s protocol. Cells were cultured for 7 days to allow
gene editing and protein depletion to occur, resulting in a
mixed population of edited and non-edited cells. 5 × 105
cells were then plated per 10 cm dish and treated with either
DMSO or 1.5 M AZD6738 for 5 days, including passag-
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ing as required. 1.5 M AZD6738 had been optimised to
kill ∼95% of non-edited control cells in this assay format,
thereby strongly enriching for resistant cells. A sgRNA tar-
geting Lrrc29 was used as a negative control as our screen
outcomes did not predict this gene to influence ATRi sen-
sitivity in Atm WT mESCs. Genomic DNA from surviv-
ing cells, alongside from non-transfected control cells, was
extracted (Invitrogen, K1820) and the sgRNA-target loci
PCR amplified using the associated primers in Supplemen-
tary Methods Table S4. The forward primer was used for
Sanger sequencing of the PCR product. Sequence traces be-
tween transfected and non-transfected cells were compared
using TIDe software (3.2.0) (44), and used to calculate the
% of each InDel (–50 bp to + 50 bp) per sample. To ac-
count for in-frame mutations likely having minimal impact
on protein expression, InDels were classified as in-frame or
out-of-frame based on whether the size of the InDel was a
multiple of 3. Undefined InDels could be the result of noise
in the Sanger sequencing trace, or InDels outside the range
–50 bp to +50 bp.
RNA-seq. RNA sequencing (RNA-seq) was performed in
mESCs using two WT biological replicates and three inde-
pendent Ccnc KO and Cdk8 KO clones. Cells were treated
for 4 h with either DMSO or 900 nM AZD6738 prior to
sample collection. A 4-hour timepoint gave the biggest win-
dow in Ccnb1 mRNA expression, which has been shown
to be prematurely upregulated upon ATR inhibition (4)
(data not shown). RNA was extracted using a RNeasy kit
with on column DNase digestion according to the manufac-
turer’s protocol (Qiagen, 74106). RNA integrity was con-
firmed using Agilent Tapestation RNA screentape, show-
ing two sharp peaks representing the 18S and 28S ribo-
somal subunits, with a 28S:18S ratio of approximately 2
(RINe > 9). Using 5 g input RNA, mRNA was iso-
lated from ribosomal RNA using the NEBNext Poly(A)
mRNA magnetic isolation module (E7490) according to the
manufacturer’s instructions. Following two rounds of en-
richment, successful isolation and sample integrity (RINe
2–3) were confirmed using high sensitivity Agilent Screen
tape. Library preparation was performed using the NEB-
Next Ultra II directional library prep kit (E7760) accord-
ing to the manufacturer’s instructions for ‘purified RNA or
clean RNA’, and using NEBnext multiplex oligos (E7335).
cDNA concentrations were measured using the Qubit ds-
DNA assay kit (Q32854), and molar concentrations calcu-
lated using the average DNA fragment size following anal-
yses on the Agilent Tapestation with high sensitivity DNA
screentape (D1000). Equal molar concentrations were mul-
tiplexed at a final concentration of 10 nM and sequenced
using single-ended reads on an Illumina Hiseq4000 system.
Due to limitations in the number of samples that could be
combined in a single multiplex for sequencing, WT sam-
ples were independently multiplexed with Ccnc KO samples,
and again with Cdk8 KO samples, in order to eliminate any
sequencing-run bias.
RNA-seq data analysis. FASTQ files were first checked
with FASTQC (version 0.11.5, http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/ (45)) for quality control.
The adaptor sequences were then removed using Trim-
momatic (version 0.38 (46)), specifying the TruSeq3-
SE.fa:2:30:10 adapters in the ILLUMINACLIP argument.
The trimmed sequences were then aligned to the reference
Mus musculus genome and annotation (build GRCm38.p6,
NCBI:GCA 000001635.8) using HISAT2 (version 2.1.0
(47)) with default settings. Gene expression levels were then
quantified from the aligned reads using featureCounts (ver-
sion 2.0.1 (48)) with the options –ignoreDup and -s 2. Ref-
erence annotation GTF file was also obtained from genome
build GRCm38.p6. Lastly, the R package DESeq2 (49) was
used for exploratory data analysis and visualisation, as well
as differential expression analyses. Reference genome se-
quence and annotation files were obtained from Ensembl
(50).
Statistical analyses. Statistical tests were performed as in-
dicated in the figure legends to determine statistical sig-
nificance in replicate comparisons. A P-value < 0.05 was
deemed statistically significant.
RESULTS
Identification and validation of factors influencing ATRi sen-
sitivity in ATM-proficient and ATM-deficient cells
To systematically interrogate drivers of ATRi efficacy in a
clinically relevant genetic background, we performed whole
genome CRISPR–Cas9 genetic screens in an isogenic pair
of Atm WT and KO mESCs with a view to finding gene-
products that, when lost, caused either hypersensitivity or
resistance to the ATRi AZD6738 (36) (Figure 1A). We
chose mESCs as our cell model in part because, compared
to other cell models that we tested, ATM loss had mini-
mal impact on cell proliferation rates (Supplementary Fig-
ure S1A), thereby facilitating the comparison of hits ob-
tained between each genotype. Furthermore, the faster pro-
liferation rates of mESCs ensured that cells underwent mul-
tiple rounds of replication and cell divisions in a 6-day
treatment window. This was important because ATRi ef-
ficacy is likely to be influenced by S-phase drug exposure
and subsequent mitotic entry (Supplementary Figure S1A).
To enhance our prospects for uncovering both resistance
and sensitivity factors, and to facilitate comparisons be-
tween both genetic backgrounds, we performed parallel
screens at doses of AZD6738 that we had determined to
equate to the IC10 and IC90 values for each cell line (as ex-
pected, Atm KO mESCs were significantly more sensitive to
AZD6738 treatment than their WT counterparts; Supple-
mentary Figure S1B). Following successful quality control
(QC) of our screens (Supplementary Figure S1C–H), ensu-
ing MAGeCK (51) bioinformatics analyses revealed a vari-
ety of factors and pathways predicted to contribute to ATRi
hypersensitivity or resistance (Figure 1B, Supplementary
Figure S2A, Supplementary Table S1). Furthermore, pre-
viously reported genes modulating sensitivity in Atm WT
cells served as positive controls, indicating the reliability of
our screens (Cdc25a for resistance (24); Atm and Trp53 for
sensitivity (14–16,52)). Notably, some gene-products whose
inactivation was recently reported to hypersensitise cells
to ATR inhibition (RNASEH2A, RNASEH2B, ERCC1,
POLE3 and POLE4 (21–23)) behaved as essential in our
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Figure 1. CRISPR–Cas9 screens using AZD6738 in Atm WT and KO mESCs. (A) Schematic of CRISPR–Cas9 screens performed in this study. (B) Drop-
out and enrichment analyses following AZD6738 treatment in Atm WT and KO mESCs. Genes were statistically ranked using MAGeCK analysis software,
and top hits with a P-value < 0.001 classified into related pathways and complexes. Dashed line = P-value of 0.001. Two MAGeCK analysis methods were
performed for both IC10 and IC90 doses, and all analyses can be found in Supplementary Table S1 and Supplementary Figure S2A. The analyses that
provided the greatest number of significant drop-out or enrichment hits (FDR < 0.1) for each genotype are presented. (C) Drop-out and enrichment
analyses following AZD6738 treatment from Figure 1B, comparing MAGeCK P-values for each gene between Atm WT and Atm KO mESCs. A P-value
of 0.001 is indicated by the dotted line. Genes in the upper right quadrant were hits in both cells lines, upper left quadrant were hits only in Atm KO cells,
and those in the bottom right quadrant were hits only in Atm WT cells. Top hits in one or both cell lines are colour coded based on the same classification
as Figure 1B.
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Figure 2. Validation of hits identified through our CRISPR–Cas9 screens. (A) Competition assays between CRISPR–Cas9 edited and non-edited cells in
response to AZD6738 treatment. Cas9-expressing mESCs were transfected with synthetic sgRNAs against the target loci, resulting in a mixed pool of edited
and non-edited cells after 7 days. Each pooled population was treated for 5 days with DMSO or 1.5 M AZD6738, with a high dose strongly enriching
for resistant cells. Genomic DNA was extracted and the sgRNA-targeted loci PCR amplified to allow editing efficiencies and % InDels (–50 bp to +50 bp)
to be calculated using TIDe software (3.2.0) (44). The control sgRNA targeted Lrrc29 which was not predicted to influence ATRi sensitivity in Atm WT
mESCs according to our screening data. (B) Results of MTT cell proliferation assays in Atm WT and KO mESCs following siRNA-depletion of YWHAE,
in response to two chemically distinct ATR inhibitors (AZD6738 and VE-822). Error bars = mean ± SEM (biological n = 3). (C) Clonogenic survivals
of ATM WT and KO A549 and FaDu cells following siRNA-depletion of CCDC6, in response to two chemically distinct ATR inhibitors (AZD6738 and
VE-822). Error bars = mean ± S.D (biological n = 3). FaDu ATM KO cells are inherently extremely sensitive to doses of VE-822 which effectively inhibit
ATR kinase activity, therefore precluding analysis of further reductions in clonogenic survival upon CCDC6 depletion.
screening conditions in mESCs, likely explaining our inabil-
ity to detect these (Supplementary Figure S2B). To more
easily compare hits obtained through our screens in Atm
KO versus WT mESCs, we directly compared the P-values
for each gene between both genotypes (Figure 1C) and gen-
erated a comprehensive list of genes predicted to enhance or
suppress ATRi efficacy in both ATM-deficient and ATM-
proficient cells (Supplementary Table S3).
Two of the strongest resistance gene hits in the Atm KO
mESCs were Ccnc and Cdk8, which encode two compo-
nents of the same complex that regulates RNAPII-mediated
transcription. Single guide-RNAs (sgRNAs) targeting both
genes were also strongly enriched in the screen outputs
from Atm WT cells, thereby highlighting the importance
of this pathway in driving AZD6738 efficacy across multi-
ple genetic backgrounds. Using CRISPR-based cell-growth
competition assays (44,53), we provisionally validated both
genes alongside various other resistance-gene hits from the
Atm WT screens that commonly acquire missense muta-
tions and/or reduced expression in cancer (Prkar1a (54–
56), Flcn (57,58), E2f8, Ccnc (59) and Cdk8 (60)) (Figure
2A). We therefore speculate that such mutations might rep-
resent secondary mutations in tumours that may appear un-
connected to DNA replication and repair yet limit ATRi
efficacy in the clinic.
Notably, we identified substantially more sensitiser and
resistance hits in the Atm WT background than in the Atm
KO mESCs (Figure 1C). Importantly, this was not due to
an inability to detect changes in cell fitness in Atm KO
cells upon gene editing, since genes encoding DNA-PK
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(Prkdc) and components of the Fanconi anaemia pathway
(FA) had a greater impact on cell fitness in Atm KO ver-
sus Atm WT mESCs in accordance with existing literature
(37,61,62) (Supplementary Figure S2C). Moreover, we val-
idated the ATM-status dependency of ATRi sensitivity us-
ing small interfering RNAs (siRNAs) against Ywhae (14–
3–3ε) (one of the strongest dropouts in WT cells only) and
Ccdc6 (one of the strongest dropouts in both Atm WT and
KO cells) in various ATM-deficient models, using two in-
dependent ATR inhibitors (AZD6738 and VE-822; Figure
2B and C). These data also supported the relevance of our
screening outputs in mESCs for understanding ATRi ef-
ficacy in human cancer cell models. Mechanistically, hits
that we selectively detected in Atm WT mESCs could in-
dicate proteins involved in ATM-regulated pathways that
are therefore epistatic with ATM loss. Alternatively, finding
fewer resistance hits in Atm KO compared to WT cells may
highlight the existence of numerous pathways that are re-
sponsible for ATRi hypersensitivity in ATM-deficient cells.
This in turn would suggest that patients with tumours har-
bouring ATM defects will be less likely to possess innate or
readily acquire resistance to AZD6738 treatment through
downregulation of, or loss-of-function mutations in, a sin-
gle other gene.
Taken together, these data underscored successful sys-
tematic identification of factors and pathways promoting
sensitivity and resistance to AZD6738, and highlighted how
these vary depending on the cell’s ATM status.
Loss of Cyclin C or CDK8 provides ATRi resistance
For ensuing mechanistic follow up studies, we focussed on
two of the strongest resistance gene hits that were com-
mon genetic modulators of ATRi efficacy in both Atm KO
and WT backgrounds: the genes encoding Cyclin C (Ccnc)
and cyclin-dependent kinase 8 (Cdk8), which comprise part
of the CDK8 kinase module (CKM) for the RNAPII me-
diator complex (Figure 1C). De novo CRISPR-mediated
gene KO of either Ccnc or Cdk8 in both Atm WT and
KO mESCs (Supplementary Figure S3A–C) produced re-
sistance to AZD6738 treatment, thereby further validat-
ing our screening results (Figure 3A, Supplementary Fig-
ure S3D). Importantly, concomitant knockout of Ccnc and
Cdk8 yielded no additive resistance, suggesting that they
function in a common pathway (Figure 3B, Supplemen-
tary Figure S3E). Supporting this, we noticed that Cdk8 KO
cells also had reduced Cyclin C levels (Supplementary Fig-
ure S3A, B), consistent with a previous report showing that
CDK8 is required for Cyclin C stability, but not vice-versa
(63).
Furthermore, we found that loss of Cyclin C or CDK8
conferred resistance to a clinical ATRi, VE-822, that is
chemically distinct from AZD6738, as well as towards the
CHK1i (LY2603618) or WEE1i (AZD1775), but not to-
wards various DNA-damaging agents that we tested: ion-
ising radiation (IR) which causes various forms of DNA
damage, the strong apoptosis inducers etoposide and carbo-
platin, as well as hydroxyurea (HU) or aphidicolin which in-
duce DNA replication stress by impairing DNA polymerase
processivity (Figure 3C, Supplementary Figure S3F–J).
This indicated that the resistance mechanism afforded by
loss of Cyclin C or CDK8 appeared specific to inhibition of
the RSR but did not act more generally in response to other
sources of replication stress or DNA damage. Notably, Cy-
clin C and CDK8 have been reported to upregulate the tran-
scription of a subset of p53-dependent genes (64). However,
rather than causing resistance, p53 loss caused sensitivity
to AZD6738, consistent with previous reports (15,16,52).
Given that CKM positively regulates the p53 downstream
responses, this is unlikely to underpin the mechanism of
ATRi resistance driven by CKM loss. To further support
this notion, we deleted CCNC or CDK8 in human U2-
OS and HAP-1 cells respectively (Supplementary Figure
S3K-L)––two cell lines that display dysfunctional p53 sig-
nalling (Supplementary Figure S3M). Loss of Cyclin C or
CDK8 in these cell lines also caused AZD6738 resistance
(Figure 3D and E), thereby supporting a p53-independent
mechanism and corroborating our findings in human can-
cer cell lines. Importantly, unperturbed Cyclin C- or CDK8-
deficient cells showed no discernible difference in cell cycle
profiles or growth kinetics compared to their WT counter-
parts in all three cellular backgrounds (Supplementary Fig-
ure S4A–C).
To assess whether CDK8 kinase activity is required for
AZD6738 treatment response, we complemented CDK8
KO HAP-1 cells with either a WT CDK8-GFP construct,
or one bearing a D173A mutation that inactivates CDK8
catalytic activity (65). We observed that the D173A mutant
provided ATRi resistance comparable to complete CDK8
loss, suggesting that CDK8 kinase activity is critical for
its function in regulating ATRi sensitivity (Figure 3F, Sup-
plementary Figure S5A-B). Accordingly, we observed that
CDK8 kinase activity was abrogated to a similar extent
in both Cyclin C and CDK8 deficient cells, as measured
by probing for phosphorylation of CDK8 targets STAT1
(pS727) and STAT5 (pS726) (66,67) (Supplementary Figure
S5C; as expected, CDK8 activity was also restored by com-
plementing cells with WT, but not D173A mutant, CDK8).
Cyclin C/CDK8 loss modulates ATRi sensitivity indepen-
dently of CDC25A and G2/M checkpoint function
CDC25A loss has been reported to provide ATRi resis-
tance by opposing the G2/M checkpoint override and pre-
mature mitotic entry caused by ATRi treatment (24). We
therefore sought to establish whether Cyclin C and CDK8
were epistatic with CDC25A regarding ATRi sensitivity.
Firstly, we assessed Cdc25a transcript levels in Cdk8 KO
and Ccnc KO mESCs, and found no change compared with
the WT cells (Figure 4A). Furthermore, de novo CRISPR-
mediated knockout of Cdc25a in Ccnc WT or Ccnc KO
backgrounds demonstrated a clear additive effect of inac-
tivating each gene on AZD6738 resistance, consistent with
Cyclin C and CDC25A acting in different pathways to pro-
mote AZD6738 resistance (Figure 4B). To test whether loss
of Cyclin C/CDK8 suppressed AZD6738-induced G2/M
checkpoint abrogation via an alternate pathway, we per-
formed pulse-chase experiments with the nucleotide ana-
logue EdU (Figure 4Ci). As expected, incubation with
AZD6738 caused faster progression of cells though mitosis
and into G1 phase, as indicated by the boxes in Figure 4Ci,
and quantified in Figure 4Cii-iii). Importantly, progression
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Figure 3. Loss of Cyclin C/CDK8 provides ATRi and CHK1i resistance. (A) Clonogenic survivals of Ccnc/Cdk8 WT/KO Atm WT/KO mESCs treated
with AZD6738, represented as AUCs (areas under the curve). Error bars = mean ± S.D (biological n = 3). Survival curves can be found in Supplementary
Figure S3D. (B) Clonogenic survivals of WT and Ccnc/Cdk8 single and dual KO mESCs treated with AZD6738. Data also represented as AUCs. Error
bars = mean ± SD (biological n = 3). (C) Clonogenic survivals of Ccnc/Cdk8 WT/KO Atm WT/KO mESCs treated with the CHK1 inhibitor LY2603618,
represented as AUCs. Error bars = mean ± SD (biological n = 3). Survival curves can be found in Supplementary Figure S3F. (D) Clonogenic survivals of
WT and CCNC KO U2-OS cells in response to AZD6738 treatment. A3/B24 clones were confirmed as WT by immunoblot analyses and genotyping after
single-cell expansions of sgRNA-transfected cells. Data also represented as AUCs. Error bars = mean ± SD (biological n = 3). (E) Clonogenic survivals
of WT and CDK8 KO HAP-1 cells in response to AZD6738 treatment. Data also represented as AUCs. Error bars = mean ± SD (biological n = 3). (F)
Clonogenic survivals of WT and CDK8 KO HAP-1 cells, complemented with WT or kinase dead (D173A) CDK8-GFP, treated with AZD6738. Data
also represented as AUCs. Error bars = mean ± SD (biological n = 3). Additional clones are shown in Supplementary Figure S5A and B. All statistical
analyses were performed using a one-way ANOVA test with multiple comparisons. P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were
deemed statistically significant.
rates from G2 to G1 were not discernibly different between
WT, Ccnc KO and Cdk8 KO mESCs, when assessed in
either the presence or absence of AZD6738 (Figure 4Cii–
iii). However, despite the G2/M checkpoint being equally
defective, we noted that micronuclei levels following 24
h treatment with AZD6738 were significantly reduced in
CCNC KO U2-OS cells as compared to WT controls (Fig-
ure 4D). These data therefore suggested that when ATR is
inhibited, Cyclin C/CDK8 promote increased DNA dam-
age that persists until mitosis, wherein it leads to increased
micronuclei formation.
Cyclin C loss reduces basal and ATRi/CHK1i-induced
DNA:RNA hybrids
CDK8 kinase activity is primarily associated with phospho-
rylating the C-terminal domain (CTD) of RNAPII and var-
ious transcription factors (68), therefore pointing towards
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Figure 4. Loss of Cyclin C/CDK8 promotes ATRi resistance independent of CDC25A or G2/M checkpoint regulation. (A) Cdc25a mRNA transcript
levels in WT and Ccnc/Cdk8 KO mESCs as assessed by RT-qPCR using two independent primer pairs. Transcript levels are normalised to the house-keeping
gene Gapdh. Cdc25a KO mESCs (24) were used as a control. Error bars = mean ± SEM (biological n = 4 WT, Cdk8 KO, Ccnc KO; n = 2 Cdc25a KO). (B)
Clonogenic survivals of isogenic WT and de novo generated Ccnc/Cdc25a single and dual KO mESCs treated with AZD6738. Error bars = mean ± SD
(biological n = 3). (C) Actively replicating S-phase Ccnc and Cdk8 WT and KO mESCs were pulse-labelled with 10 M EdU for 30 min prior to release
into media containing DMSO or 900 nM AZD6738 for 6 h. Error bars = mean ± SEM (biological n = 3 Ccnc KO, n = 4 Cdk8 KO). (i) Schematic of
experimental design and gating strategy using FACS profiles in WT mESCs. (ii) Cell cycle distributions based on DAPI histograms. iii) Distribution of
EdU positive cells between G1/S and G2/M 6 h after removal of EdU. DNA content 2N = G1, 4N = G2/M. EdU positive cells were actively replicating
at the time of EdU labelling. (D) Mean number of micronuclei/cell after 24 h treatment with DMSO or 1.5 M AZD6738 in U2-OS CCNC WT and
KO cells. Error bars = mean ± SD (biological n = 3). Arrows indicate micronuclei in the representative images. Representative images were taken at 40×
magnification, scale bars = 12 m. All statistical analyses were performed using a one-way ANOVA test with multiple comparisons, except in Figure 3B
where a two-way ANOVA test was used. P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were deemed statistically significant.
transcriptional control as the mechanism by which Cyclin
C/CDK8 loss promotes ATRi resistance. Previous stud-
ies on CKM in mammalian cells have established that its
depletion leads to transcriptome changes but not a genome-
wide reduction in RNAPII activity (69–71). In line with this,
we observed no consistent reduction in mRNA synthesis or
abundance of elongating RNAPII in our Cyclin C/CDK8-
deficient cells as compared to controls (Supplementary Fig-
ure S6A-F). We therefore probed for specific changes in the
transcriptome by performing RNA-seq in WT, Cdk8 KO
and Ccnc KO mESCs following DMSO or AZD6738 treat-
ment. While quality control metrics and biological controls
supported the reliability of our data (Supplementary Fig-
ure S6G–J), we did not identify any transcripts that were
significantly differentially regulated upon AZD6738 treat-
ment in both Ccnc and Cdk8 KO, but not WT, cells (Sup-
plementary Table S4). Similarly, Gene Ontology analyses of
proteins whose transcripts were upregulated or downregu-
lated in a treatment-independent manner in both Cdk8 and
Ccnc KO clones compared to WT mESCs did not provide
a clear explanation why the Ccnc/Cdk8 KO cells are ATRi
resistant (Supplementary Table S4).
Instead, we speculated that loss of Cyclin C/CDK8 may
reduce collisions between the transcription and replication
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Figure 5. Cyclin C loss supresses DNA:RNA hybrid formation in response to ATRi and CHK1i. (A) Mean number of RNH1(D210N)-GFP foci/nuclei
normalised to untreated NT siRNA levels in response to AZD6738 or CHK1i (LY2606368) treatment, following siRNA-depletion of Cyclin C. Error
bars = mean ± SD (biological n = 2). Representative images are of RNH1(D210N)-GFP foci in EdU positive cells, following treatment with DMSO,
AZD6738 for 24 h, or CHK1i for 4 h. Scale bars = 12 m. A full field of view is provided in Supplementary Figure S7C which also highlights the
heterogeneity of foci induction in Cyclin C-depleted cells treated with CHK1i. SiRNAs targeting CDK8 were also tested but resulted in the accumulation
of cells in G1 which may bias the experimental outcome (Supplementary Figure S7A and B). (B) Clonogenic survivals of RECQL5-depleted WT and
CCNC KO U2-OS cells treated with AZD6738. Error bars = mean ± SD (biological n = 3). Statistical analyses were performed using a two-way ANOVA
test by comparison to CCNC WT cells transfected with the control (NT) siRNA. P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were deemed
statistically significant.
machineries upon ATR inhibition, whereby transcription-
replication conflicts are associated with DNA:RNA hybrid
formation and genome instability, primarily through caus-
ing replication fork collapse (9,72). We therefore used a
reporter system employing catalytically dead RNase H1
(RNH1(D210N) (39))––which binds to but does not pro-
cess DNA:RNA hybrids - to quantify DNA:RNA hybrid
levels in response to ATR or CHK1 inhibition following de-
pletion of Cyclin C. Since CDK8 depletion caused signifi-
cant accumulation of U2-OS cells in G1 and also reduced
Cyclin C protein levels (63) (Supplementary Figure S3A-B
and Supplementary Figure S7A and B), we focused largely
on Cyclin C loss for further studies. Strikingly, this revealed
that both basal and ATRi/CHK1i-induced DNA:RNA hy-
brid levels were markedly reduced in cells depleted of Cy-
clin C (Figure 5A; as shown in Supplementary Figure S7C,
DNA:RNA hybrids formed in each case in S-phase cells).
In light of these data, we hypothesised that Cyclin C loss
alleviated the rate of transcription-replication encounters
that are enhanced upon ATRi or CHK1i treatment, as op-
posed to promoting DNA:RNA hybrid resolution. Sup-
porting this, RECQL5, which is reported to limit and re-
solve transcription-replication conflicts (73,74), was iden-
tified as an ATRi sensitiser in our CRISPR–Cas9 screens
(Figure 1B). Depletion of RECQL5 enhanced sensitivity
to AZD6738 and rescued the ATRi resistance observed
upon Cyclin C loss, with CCNC-knockout RECQL5-
depleted cells showing equivalent sensitivity to WT cells
transfected with a control siRNA (Figure 5B). Taken to-
gether, these results showed that Cyclin C loss counteracts
DNA:RNA hybrid formation caused by ATR and CHK1
inhibition in S-phase, suggesting that counteracting or re-
ducing transcription-replication conflicts improved cell sur-
vival.
Loss of Cyclin C suppresses replication stress in response to
ATR or CHK1 inhibition
Both transcription-replication conflicts and DNA:RNA hy-
brids have been established as sources of genome instabil-
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ity, largely through promoting replication fork stalling and
collapse into single-ended DSBs (seDBSs) (9,10). In the ab-
sence of replication fork protection, replication stress can
also cause RPA exhaustion, leading to nuclease processing
of exposed ssDNA, global replication fork breakage and
ATM activation (11). Importantly, ATR and CHK1 play
pivotal roles in counteracting this phenomenon, known
as replication catastrophe, by limiting global origin firing
and promoting nucleotide synthesis. We therefore assessed
whether Cyclin C loss decreased replication stress and ul-
timately prevented replication catastrophe in the presence
of ATRi or CHK1i. To assess this, we monitored RPA32
chromatinisation and histone H2AX Ser-139 phosphory-
lation (H2AX) over time in CCNC WT and KO U2-OS
cells treated with ATRi or CHK1i. RPA32 hyper-positive
cells were indicative of replication stress, while pan-nuclear
RPA32 and H2AX dual-positive cells detected at later
time points suggested replication catastrophe (11) (Fig-
ure 6A). As expected, we found that RPA32 and H2AX
accumulation occurred primarily in EdU positive cells, con-
firming that active DNA replication in S-phase is required
for DNA damage generation. We observed that Cyclin C
loss reduced replication stress (RPA chromatinisation) in-
duced by either ATR or CHK1 inhibition (Figure 6Bi;
Supplementary Figure S8A and B). In CCNC KO cells,
ATRi-induced replication stress remained below that ob-
served in WT cells for the full 24 h treatment window tested
(Supplementary Figure S8C), with this reduction presum-
ably sufficient to limit under-replicated DNA from enter-
ing mitosis as indicated by the reduced micronuclei forma-
tion in CCNC KO cells at 24 h (Figure 4D). On the other
hand, CHK1i-induced replication stress resulted in replica-
tion catastrophe, consistent with the more potent induction
of DNA:RNA hybrid formation following treatment with
CHK1i compared with ATRi treatment. In agreement with
the reduction in DNA:RNA hybrids observed in Cyclin C-
depleted cells, we observed a delayed induction of replica-
tion catastrophe in CCNC KO compared to WT cells upon
CHK1 inhibition (Figure 6Bi-ii). In line with this, in CCNC
KO cells we observed delayed kinetics of RPA32 phospho-
rylation on Ser-4/8, which has been associated with repli-
cation fork collapse and seDSB (single-ended DSB) forma-
tion (11,75), as well as delayed ATM activation detected by
its auto-phosphorylation on Ser-1981 (Figure 6C). This oc-
curred in a dose-dependent manner, with CCNC KO cells
experiencing a delayed onset of DNA damage by several
hours at lower CHK1i doses (Supplementary Figure S8D
and E). A similar delay in H2AX formation and Ser-4/8
RPA32 phosphorylation was observed in Ccnc and Cdk8
KO mESCs as compared to WT control cells (Supplemen-
tary Figure S8F). Importantly, given that Cyclin C loss only
delayed the onset of CHK1i-induced replication catastro-
phe, we assessed whether this was sufficient to increase cell
survival. Indeed, short-term treatment with either ATRi or
CHK1i still induced cell death in CCNC WT cells, whereas
CCNC KO cells retained the resistance phenotype observed
with continuous ATRi or CHK1i treatment (Figure 6D and
E, Supplementary Figure S8G and H).
To assess at which stage in S-phase DNA damage was
occurring in our studies, we probed for H2AX following
CHK1 inhibition using flow cytometry and gated the cells
as early or late S-phase based on EdU and DAPI intensity.
This revealed that CHK1i-treated CCNC WT cells accumu-
lated with DNA damage in early S-phase, whereas in CCNC
KO cells H2AX formed only at later time points and in
both early and late S-phase (Figure 6F, Supplementary Fig-
ure S8I). In CCNC WT cells, this was associated with a dra-
matic reduction in EdU incorporation by 240 minutes, indi-
cating that any cells capable of entering mitosis would do so
with an under-replicated genome. Conversely, despite accu-
mulating DNA damage (H2AX) by 240 min, CCNC KO
cells appeared more likely to enter mitosis with a near-fully
replicated genome, therefore supporting a model in which a
delay in replication catastrophe is sufficient to promote cell
survival. Together, these data suggested that Cyclin C loss
in S-phase alleviates replication stress induced by ATR or
CHK1 inhibition, and that this enhances cell survival.
Cyclin C loss alleviates transcription-associated replication
stress
Although DNA:RNA hybrid formation and transcription-
replication conflicts are often linked, they are not a single
event or interchangeably defined, with both being able to
promote genome instability through replication fork col-
lapse. Furthermore, DNA:RNA hybrids and transcription-
replication conflicts can be both caused by, or cause, the
other, and various sources of DNA:RNA hybrids have been
identified (76). We therefore deemed it important to dis-
tinguish whether the Cyclin C associated replication stress
arising from ATRi or CHK1i treatment was caused by col-
lisions between transcription and replication machineries,
the DNA:RNA hybrids, or both. To investigate whether the
DNA:RNA hybrids were themselves the cause, we assessed
the impact on ATRi/CHK1i-induced replication stress of
overexpressing RNase H1 which degrades DNA:RNA hy-
brids (Supplementary Figure S9A). Through these exper-
iments, we observed no significant impact of RNase H1
overexpression on cell survival, replication stress or repli-
cation catastrophe following CHK1i or ATRi treatment in
the presence or absence of Cyclin C (Figure 7A–C, Supple-
mentary Figure S9B). These data therefore indicated that
the DNA:RNA hybrids themselves were likely not directly
responsible for ATRi or CHK1i-induced replication stress
and cell death, but instead suggested that the upstream
physical collisions between transcription and replication
machineries were promoting genome instability. Further-
more, Cyclin C depletion similarly rescued the impact of
ATRi or CHK1i treatment in both RNase H1 un-induced
and RNase H1 overexpressing cells, thereby supporting the
idea that Cyclin C loss acts upstream to limit DNA:RNA
hybrid formation rather than acting at the level of their res-
olution.
Finally, to assess a role for transcription-replication col-
lisions in Cyclin C-associated replication stress, we pre-
incubated cells with the transcription inhibitor DRB (7,77–
79) at a dose and time-points that reduced transcription-
replication collisions as indicated by a proximity ligation
assay (PLA) between RNAPII and the DNA replication
component PCNA, yet had minimal or no impact on the
cell cycle (Supplementary Figure S9C–E). Accordingly, we
found that DRB pre-treatment reduced ATRi- and CHK1i-
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Figure 6. Cyclin C loss supresses replication stress in response to ATRi and CHK1i. (A) Schematic of replication stress and replication catastrophe, which
can be monitored by increased RPA32 chromatinisation (replication stress), followed by detection of H2AX in RPA32 hyper-positive cells at later time
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induced RPA chromatinisation in CCNC WT cells to levels
similar to those observed in CCNC KO cells (Figure 7D,
Supplementary Figure S9F). We also observed a similar de-
lay in the kinetics of H2AX, CHK1 pSer-345 and RPA
pSer-4/8 following CHK1i treatment in DRB pre-treated
CCNC WT cells comparable with CCNC KO cells (Fig-
ure 7E). Notably, Cyclin C loss or DRB pre-treatment did
not impact on IR-induced DNA damage as indicated by
similar levels of H2AX, CHK1 pSer-345 and ATM pSer-
1981 (Supplementary Figure S9G). This is consistent with
our extended cell survival data (Supplementary Figure S3J)
and underlines a specific impact of Cyclin C on replication
stress-induced DNA damage. Overall, these data supported
a major role for transcription-associated replication stress
in driving ATR and CHK1 inhibitor efficacy and highlight
Cyclin C and CDK8 as key factors capable of modulating
this response.
DISCUSSION
ATR inhibitors are in clinical trials for the treatment of
cancers (12), with patient selection hypotheses including
ATM deficiency (13–16) and high replication stress (17–
20). To identify mechanisms of ATRi efficacy in cells with
clinically relevant mutations, we performed the first whole-
genome ATRi CRISPR–Cas9 screens in paired isogenic
ATM-proficient and ATM-deficient cells. Through this ap-
proach, we identified known as well as novel factors which,
when lost, provided either sensitivity or resistance to ATRi
in one or both genetic backgrounds. Of these hits, sev-
eral modulated ATRi sensitivity independent of ATM ex-
pression, including Trp53 and Ccdc6 (sensitivity) and Ccnc
and Cdk8 (resistance). These genes highlight mechanisms of
ATRi efficacy that may drive cell death across multiple tu-
mour types. Notably, we identified substantially fewer gene
hits in Atm KO compared to WT cells, which may reflect
the numerous interplays between ATR and ATM to reg-
ulate DNA repair, DNA replication and cell cycle check-
point engagement. It is therefore plausible that loss of a
single protein is in most instances insufficient to promote
ATRi resistance in ATM-deficient cells, as cell death can
still be driven through deregulation of another critical path-
way. By highlighting that it may be difficult to generate re-
sistance phenotypes in this setting, our findings therefore
support the targeted use of ATRi against tumours with im-
paired ATM function, and propose the attraction of inhibit-
ing ATR rather than other DDR factors such as PARP in
ATM-deficient tumours, where resistance can be imparted
by single inactivation of various genes due to one primary
mode of cell death (38). Alternatively, certain hits arising
in our screens that increased sensitivity in Atm WT but not
Atm KO cells may encode proteins that act in the same path-
way as ATM to modulate ATRi efficacy, and therefore ex-
hibit an epistatic relationship with ATM loss. Such compo-
nents represent candidates for identifying ATM-mediated
back-up pathways that can compensate in the absence of
functional ATR. We note however that, in some cases, an
increased impact on cell fitness in Atm KO mESCs may
have affected our ability to detect drug-dependent changes
in the sgRNA abundances of certain genes in Atm KO
cells. We therefore encourage the cross-referencing of ATM-
dependant hits with our essential-gene screen outcomes
when prioritising candidates for further study. Neverthe-
less, through validating several such factors and their ATM-
status dependency, we believe that our data provide a re-
source to inform future studies into interplays between the
ATR and ATM kinases, as well as the clinical use of ATR
inhibitors.
Our studies have shown that loss of Cyclin C or CDK8
provides ATRi resistance in both ATM-proficient and
ATM-deficient cells. Cyclin C and CDK8 form part of
the CDK8 kinase module of the RNAPII mediator com-
plex, and deregulation of either gene has functional con-
sequences for cancer development (59,60,80,81). We found
that Cyclin C- or CDK8-deficient cells were selectively re-
sistant to inhibitors of the RSR (ATR, CHK1 and WEE1)
but did not function via regulation of CDC25A or re-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
points (replication catastrophe). (B) Chromatinised RPA32 and H2AX intensities in EdU positive nuclei measured by immunofluorescence in CCNC
WT and KO U2-OS cells. S-phase cells were labelled with 10 M EdU for 30 min prior to pre-extraction and fixation. Representative images can be found
in Supplementary Figure S8A. (i) Mean intensities normalised to non-treated WT cells, following 0–240 min treatment with 50 nM CHK1i (LY2603638)
or 1 M AZD6738 (biological n = 3). Mean intensities for each replicate are displayed as black triangles and were used for the overall mean calculations
and statistical analyses. Mean intensities for each individual cell were normalised to the mean intensity of non-treated WT cells in each replicate, and all
three replicates overlaid in blue (CCNC WT), red (CCNC KO A10) or orange (CCNC KO A11) for visualisation of single-cell data. These data are also
normalized to the non-treated conditions of each individual cell line (Supplementary Figure S8B) to highlight that the suppression of replication stress upon
ATRi/CHK1i in CCNC KO cells is independent of any differences in basal intensities. Statistical analyses were performed using one-way ANOVA analyses
with multiple comparisons. P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were deemed statistically significant. ii) Representative example
of replication catastrophe occurring in CCNC WT, but not KO, cells following 120 min CHK1i treatment. Mean chromatinised RPA32 and H2AX
intensities for each EdU-positive cell are presented as a scatter plot. (C) Immunoblots for markers of DSB formation, indicative of replication catastrophe.
CCNC WT and KO U2-OS cells were treated for 0–240 min with 50 nM CHK1i (LY2603638) prior to lysis. *Both bands are modified forms of CHK1
as indicated by the shift in total protein. (D) Clonogenic survivals of CCNC WT and KO U2-OS cells treated with AZD6738 for 6, 16 or 24 h prior to
drug wash-out, represented as AUCs. Error bars = mean ± SD (biological n = 3). Survival curves can be found in Supplementary Figure S8G. Statistical
analyses were performed using a two-tailed unpaired Student’s t-test. P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were deemed statistically
significant. (E) Clonogenic survivals of CCNC WT and KO U2-OS cells treated with CHK1i LY2603638 for 2, 4 or 6 h prior to wash-out, represented as
AUCs. Error bars = mean ± SD (biological n = 3). Survival curves can be found in Supplementary Figure S8H. Statistical analyses were performed using
a two-tailed unpaired Student’s t-test. P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were deemed statistically significant. (F) Representative
FACS plots gated for cell-cycle phase using EdU versus DAPI intensity (blue), overlaid with H2AX positive cells (red) after 0–240 min treatment of
CCNC WT and KO U2-OS cells with 50 nM CHK1i (LY2603638). DNA content 2N = G1, 4N = G2/M. S-phase cells are EdU positive following 30 min
treatment with 10 M EdU, and are gated into early (2N–3N) or late (3N–4N) S-phase. Numbers in red indicate the % of the total population that are
H2AX positive and in the associated cell-cycle phase. A representative gating strategy for H2AX positive cells is shown in Supplementary Figure S8I.
Quantification of % cells that are H2AX positive and in the associated cell-cycle phase in CCNC WT and KO cells following CHK1i treatment is also
provided. Error bars = mean ± SD (biological n = 3).
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Figure 7. Cyclin C-associated replication stress is transcription-dependent. (A) Clonogenic survivals of U2-OS cells ± Cyclin C depletion ± doxycycline
induction of RNH1-GFP, treated with AZD6738. Error bars = mean ± SD (biological n = 3). Statistical analyses were performed using two-way ANOVA
analyses. P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were deemed statistically significant. (B) Mean chromatinised RPA32 and H2AX
intensities in EdU positive nuclei measured by immunofluorescence in WT or Cyclin C-depleted U2-OS cells, ± doxycycline-induced RNH1-GFP ex-
pression, treated for 0–240 min with 50 nM CHK1i (LY2603638) or 1 M AZD6738. S-phase cells were labelled with 10 M EdU for 30 min prior to
pre-extraction and fixation. Mean intensities for each replicate are displayed as black triangles and were used for the overall mean calculations and sta-
tistical analyses. Mean intensities for each individual cell were normalised to the mean intensity of non-targeted siNT cells in each replicate, and all three
replicates overlaid for visualisation of single-cell data. Statistical analyses were performed using one-way ANOVA analyses with multiple comparisons.
P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were deemed statistically significant. (C) Immunoblots for markers of DSB formation, in-
dicative of replication catastrophe. U2-OS cells were siRNA-depleted of Cyclin C, or transfected with the control NT siRNA, and RNH1-GFP expression
induced by the addition of doxycycline 24 h prior to treatment with 50 nM CHK1i (LY2603638) for 0, 2 or 4 h. CCNC siRNA #1 was used here, and the
results obtained using siRNA #2 are provided in Supplementary Figure S9B. (D) Mean chromatinised RPA32 intensities in EdU positive nuclei measured
by immunofluorescence in CCNC WT and KO U2-OS cells, normalised to non-treated WT cells (biological n = 3). Cells were pre-incubated with DMSO
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establishment of the G2/M checkpoint (24). Instead, we
discovered that depletion of Cyclin C (which is also desta-
bilised in the absence of CDK8) reduced basal levels
and ATRi- or CHK1i-induced DNA:RNA hybrids in S-
phase. We predict that the reduction in DNA:RNA hy-
brids upon Cyclin C depletion reflects fewer collisions be-
tween transcription and replication machineries, which can
cause genome instability through replication fork collapse
and seDSB formation (9). Notably, eukaryotic transcrip-
tion and replication are normally spatio-temporally co-
ordinated in S-phase (82–85), and the location and regu-
lation of DNA replication origins are also critical for lim-
iting transcription-replication conflicts (7,72). By deregu-
lating dormant-origin firing, ATRi or CHK1i are therefore
likely to increase the probability of transcription-replication
collisions and promote genome instability. Furthermore,
abrogated ATR or CHK1 activity may exacerbate the
DNA damage by increasing replication fork stalling (86)
or by preventing effective replication fork stabilisation and
restart, whereby ATR is activated at R-loop-stalled replica-
tion forks and is required for cell survival (43). Interestingly,
we also identified that loss of factors such as YTHDF2
and RECQL5 increased ATRi sensitivity in our screens.
These hits therefore support a general connection between
the regulation of DNA:RNA hybrids and/or transcription-
replication collisions and ATRi efficacy, since YTHDF2
regulates DNA:RNA hybrid stability to prevent their ac-
cumulation (87), and RECQL5 promotes the resolution of
transcription-replication conflicts (73,74). Given that Cy-
clin C depleted cells had reduced basal levels of DNA:RNA
hybrids, correlating with reduced ATRi/CHK1i-induced
hybrid formation, it is possible that basal DNA:RNA hy-
brid levels could be used as a phenotypic biomarker in pa-
tient tumour samples to predict ATR and CHK1 inhibitor
efficacy.
Correlating with reducing DNA:RNA hybrid formation,
Cyclin C or CDK8 loss lowered ATRi- or CHK1i-induced
replication stress. Consequently, we found that Cyclin C loss
lowered ATRi-induced micronuclei formation, presumably
as the reduction in replication stress was sufficient to limit
under-replicated DNA from entering mitosis, which would
be exacerbated upon G2/M checkpoint abrogation. On the
other hand, CHK1 inhibition induced replication catastro-
phe, which was delayed in CCNC KO compared with WT
cells. Notably, this delay was sufficient to promote cell sur-
vival in CCNC KO cells, emphasising how modulating the
extent of replication stress in S-phase is sufficient to influ-
ence ATRi- and CHK1i-induced cell death. Importantly, we
found that the impact of Cyclin C loss on replication stress
and/or replication catastrophe could be phenocopied by
pre-incubating cells with the transcription inhibitor DRB,
but not by overexpressing RNase H1, therefore further
highlighting a partial transcription-dependency of ATRi
or CHK1i-induced replication stress that is alleviated by
Cyclin C loss. Our data therefore highlight an important,
and regulatable, role of transcription-associated replica-
tion stress that contributes to overall ATRi or CHK1i ef-
ficacy. We hypothesise that this is due to Cyclin C/CDK8
loss limiting transcription-replication conflicts, which oth-
erwise increase upon inhibition of the RSR and potenti-
ate genome instability and cell death. Correspondingly, Cy-
clin C loss did not rescue sensitivities towards aphidicolin
or hydroxyurea, which cause replication stress yet reduce
transcription-replication encounters (72), thereby support-
ing a specific role for Cyclin C loss in counteracting repli-
cation stress associated with transcription. Interestingly, al-
though Cyclin C and CDK8 have largely been associated
with transcriptional roles that could underpin this mecha-
nism, both proteins have been recently implicated in DNA
replication origin firing (88,89), which could contribute to
the reduction in transcription-replication conflicts upon
Cyclin C/CDK8 loss. Furthermore, although we did not
observe a global reduction in RNAPII activity upon Cyclin
C or CDK8 loss, local transcriptional control is now well
documented in response to various DNA lesions includ-
ing DSBs (76,90). The ATR homologue (Mec1) in budding
yeast has also been reported to promote RNAPII degrada-
tion via INO80/PAF1 upon replication stress in order to
limit transcription-replication conflicts (91). It is therefore
intriguing to speculate that Cyclin C/CDK8 may provide an
additional avenue of such regulation, for example through
negative regulation by ATR to coordinate transcription
with ongoing replication or replication stress. While such
a model will require further investigation, we note that con-
served ATM/ATR SQ phosphorylation motifs exist at the
extreme C-terminus of Cyclin C and provide attractive tar-
gets for regulation by ATR.
In summary, our studies have provided a comprehensive
overview of genes that, when inactivated, enhance or dimin-
ish ATRi efficacy, and highlighted how in some instances,
but not others, these effects depend on functional ATM sig-
nalling. Further studies of various factors identified by our
screens could facilitate successful stratification of cancer pa-
tients and/or elucidate new ATM-dependent pathways that
compensate in the absence of functional ATR. Crucially,
our results have highlighted the role of the RSR pathway
in curtailing replication stress associated with transcription-
replication encounters, and have shown that factors that ei-
ther alleviate or enhance transcription-associated replica-
tion stress significantly influenced sensitivity to ATRi or
CHK1i in ways that might in due course be exploitable in
the clinical arena.
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
or 100 M DRB for 2 h prior to 2 h co-treatment with DMSO, 1 M AZD6738 or 50 nM CHK1i (LY2603638). S-phase cells were labeled with 10 M
EdU for 30 min prior to pre-extraction and fixation. Mean intensities for each replicate are displayed as black triangles and were used for the overall
mean calculations and statistical analyses. Mean intensities for each individual cell were normalised to the mean intensity of non-treated WT cells in each
replicate, and all three replicates overlaid for visualisation of single-cell data. Statistical analyses were performed using one-way ANOVA analyses with
multiple comparisons. P-values < 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were deemed statistically significant. (E) Immunoblots for markers of
DSB formation, indicative of replication catastrophe. CCNC WT and KO U2-OS cells were pre-incubated with 100 M DRB for 2 h prior to co-treatment
with 50 nM CHK1i (LY2603638) for the time-periods indicated. Control cells were treated with DMSO in parallel with the 4 h CHK1i incubation.
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